In vitro activity of imipenem-relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance United States 2015-2017
Abstract
OBJECTIVES
Antimicrobial resistance including multidrug-resistance (MDR) is increasing especially among Gram-negative bacilli. New agents are needed to treat infections caused by these pathogens. For this report, the activity of imipenem-relebactam was assessed against Gram-negative bacilli from intraabdominal infections (IAIs) and urinary tract infections (UTIs) submitted to the SMART (Study for Monitoring Antimicrobial Resistance Trends) global surveillance program in the United States from 2015 to 2017.
METHODS
Broth microdilution MICs for imipenem-relebactam and comparators were determined by a central laboratory against isolates of non-Proteeae Enterobacteriaceae (NPE) and Pseudomonas aeruginosa. Imipenem-relebactam MICs were interpreted using United States Food and Drug Administration (FDA) breakpoints.
RESULTS
99.5% of NPE isolates collected from patients with IAIs (n = 3,633) and UTIs (n = 3,038) were susceptible to imipenem-relebactam, as were 77.9% of imipenem-nonsusceptible, 96.3% of KPC-positive, and 98.7% of MDR isolates from IAIs and UTIs combined. 96.7% of IAI isolates (n = 486) and 96.4% of UTI isolates (n = 360) of P. aeruginosa were susceptible to imipenem-relebactam, as were 85.0% of imipenem-nonsusceptible and 87.3% of MDR isolates from IAIs and UTIs combined. Percent susceptibility to imipenem-relebactam for cefepime-, ceftazidime-, and piperacillin-tazobactam-nonsusceptible isolates was 98.3-98.8% for NPE and 87.3-90.0% for P. aeruginosa.
CONCLUSIONS…
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.